Adocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.
The randomised, double-blind, multicentre, outpatient study enrolled 252 diabetic patients from India with a chronic diabetic foot ulcer. In addition to standard of care, each group of patients was treated every two days for a maximum of 20 weeks with either a placebo spray (saline solution) or a spray containing BC PDGF. However, after this time, BC PDGF did not perform better than the placebo and therefore did not meet the primary endpoint.
The company’s stock price, which had lately reacted favourably to the publication of the financial results, took a hit. Share prices fell by almost 20 percent.